Risk Materials

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

Febuxostat DHPC - Increased risk of cardiovascular and all-cause mortality

DHPC describing the increased risk of cardiovascular death and all-cause mortality in patients treated with febuxostat in the CARES study.

Send us feedback

If you would like to make a comment or send us feedback on this material, click here.